Introduction
============

Lung cancer is a type of malignant tumor, which is one of the most life-threatening to humans. The morbidity and mortality rates in men with lung cancer are the highest of all types of malignancy, and lung cancer has the second highest following breast cancer in women ([@b1-mmr-16-06-9464]). Smoking is the major cause of lung cancer ([@b2-mmr-16-06-9464]) and accounts for 85% of lung cancer cases in the world ([@b3-mmr-16-06-9464]). Lung cancer includes small-cell lung carcinoma and non-small-cell lung carcinoma (NSCLC) ([@b4-mmr-16-06-9464]), and lung adenocarcinoma is a type of NSCLC, which is found in peripheral lung tissue ([@b1-mmr-16-06-9464]). It is the most common type of lung cancer in smokers and in those who have never smoked ([@b5-mmr-16-06-9464]). Lung adenocarcinoma grows slowly and usually forms small masses, however, they readily metastasize at the early stage ([@b6-mmr-16-06-9464]).

Cancer is caused by genetic and environmental factors, and \~8% of lung cancer cases are caused by genetic factors ([@b7-mmr-16-06-9464]). Genetic and environmental factors can damage DNA to alter the epigenetics, which affects the normal functions of cells, including DNA repair, cell proliferation and apoptosis ([@b8-mmr-16-06-9464]). There have been numerous studies investigating the association between gene variation and lung adenocarcinoma. The epidermal growth factor receptor and Kristen rat sarcoma viral oncogene homolog have been identified as mutations in lung adenocarcinoma as important driver genes ([@b9-mmr-16-06-9464]). In addition, single nucleotide polymorphisms (SNPs) have been found to be associated with lung cancer, including colony-stimulating factor 1 receptor, tumor protein p63 and co-repressor interacting with RBPJ1 ([@b10-mmr-16-06-9464]). Successful mapping of the human genome and the emergence of next-generation sequencing technology have assisted in the identification of specific variations associated with disease comprising SNPs, insertions and deletions (InDels), structure variations (SVs) and copy number variations (CNVs). This has already assisted in understanding and investigating several diseases, including melanoma ([@b11-mmr-16-06-9464]), lung cancer ([@b12-mmr-16-06-9464]), breast cancer ([@b13-mmr-16-06-9464]) and acute myelogenous leukemia ([@b14-mmr-16-06-9464]), and has also assisted in disease diagnosis, screening of drug targets and prediction of disease risk.

In the present study, the genome variations of four tumor tissues from different patients with lung adenocarcinoma were detected, using a whole genome re-sequencing method performed on the Illumina HiSeq Xten platform. From this, the SNPs, InDels, SVs and CNVs from these four samples were identified, and the SNPs and InDels were annotated, respectively.

Patients and methods
====================

### Patient samples and DNA extraction

Tumor samples were collected from four patients with lung adenocarcinoma. The four patients were all diagnosed with lung adenocarcinoma using pathological methods and were classified to have stage IV tumors, as bony metastases had occurred prior to diagnosis. All were treated with chemotherapy only ([Table I](#tI-mmr-16-06-9464){ref-type="table"}). Written informed consent was obtained from all patients. The study was approved by the ethics committee of Shanghai Tongji Hospital (Shanghai, China). Genomic DNA was extracted from tumor samples using standard phenol/chloroform extraction methods ([@b15-mmr-16-06-9464]). Agarose gel electrophoresis was used to confirm that the DNA samples were not degraded and that RNA was not contaminated. The quality and quantity of DNA were assessed using a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific, Inc., Waltham, MA, USA) and Qubit^®^ 2.0 Fluorometer (Thermo Fisher Scientific, Inc.), following which the DNA samples with optical density values between 1.8 and 2.0, and a content \>1.5 µg were used for library construction.

### Library construction and sequencing

The present study was performed by Beijing Novogene Bioinformatics Technology Co., Ltd, Beijing, China ([www.novogene.com/](www.novogene.com/)). Briefly, the qualified DNA samples were randomly sheared into DNA fragment sizes of 350 bp using the Covaris S220 Focused UItrasonicator (Covaris, Woburn, MA, USA), and library construction was performed according to the manufacturer\'s protocol of the TruSeqDNA Library Construction kit (Illumina, Inc., San Diego, CA, USA). The Qubit^®^ 2.0 Fluorometer was used first for preliminary quantification following the completion of library construction, following which the Agilent 2100 Bioanalyzer (Agilent Technologies, Inc., Waldbronn, Germany) was used for determining the insert size of the library. This was followed by accurate quantification using the quantitative polymerase chain reaction method to ensure the library effective concentration was \>2 nM. Sequencing was performed using the Illumina HiSeq Xten platform (Illumina, Inc.) to obtain the raw reads. Reads with adapter sequences or of low quality were filtered out to obtain clean reads, which were used in the following analysis.

### Read mapping and identification of SNPs, InDels, SVs and CNVs

The high quality filtered reads were mapped to the reference genome UCSC hg19 ([@b16-mmr-16-06-9464]) using BWA 0.7.8-r455 software ([@b17-mmr-16-06-9464]). The initial alignment results underwent duplicate removal, local realignment and base quality recalibration processing using Picard 1.111 ([sourceforge.net/projects/picard/](sourceforge.net/projects/picard/)), GATK v3.1 ([software.broadinstitute.org/gatk/](software.broadinstitute.org/gatk/)) ([@b18-mmr-16-06-9464]) and SAMtools 1.0 ([samtools.sourceforge.net](samtools.sourceforge.net)) ([@b19-mmr-16-06-9464]), respectively. The effective data were evaluated for the sequence read depth and coverage of the clean reads mapping to the reference genome. SAMtools 1.0 software ([@b19-mmr-16-06-9464]) was used to identify SNPs and InDels (fragment size of insertion or deletion \<50 bp), estimate the accuracy of SNP data with the transition/transversion ratio (ts/tv), with the whole genome ratio being \~2.2 ([@b20-mmr-16-06-9464]), and matching these SNPs and InDels to the SNP database (dbSNP) ([www.ncbi.nlm.nih.gov/projects/SNP/](www.ncbi.nlm.nih.gov/projects/SNP/)) ([@b21-mmr-16-06-9464]). The identification of SVs was performed using Breakdancer 1.4.4 software ([genome.ustl.edu/tools/cancer-genomics/](genome.ustl.edu/tools/cancer-genomics/)) ([@b22-mmr-16-06-9464]), containing large fragments of deletions, insertions, duplication and copy number variants, inversion and translocation. CNVs were identified using Control-FREEC v6.7 software ([bioinfo.curie.fr/projects/freec/tutorial.html](bioinfo.curie.fr/projects/freec/tutorial.html)) ([@b23-mmr-16-06-9464]), containing deletions and duplications.

Results
=======

### Genome sequencing and mapping to the reference genome hg19

Genome DNA was extracted from tumor tissues of four patients with lung adenocarcinoma and genome sequencing was performed with the Illumina HiSeq Xten platform. A total of 415.98 G raw data was generated on 25 paired-end lanes, and an average of 693,316,202 raw reads were obtained for each sample, clean reads accounted for \~99.88% of the original data. A Phred quality score is a measure of the quality of the identification of the nucleobases generated by automated DNA sequencing. Phred quality scores Q are defined as a property which is logarithmically related to the base-calling error probabilities P, Q=-10 log~10~ P ([@b24-mmr-16-06-9464]). The proportion of four bases was 86--91% when the Phred score was \>30, amongst which GC content accounted for 40.92--43.71% ([Table II](#tII-mmr-16-06-9464){ref-type="table"}).

The numbers of filtered clean reads were 620,492,220, 694,563,450, 679,993,278 and 774,771,688 for YJY, GMY, ZCG and JLY2, of which 96.38, 97.20, 97.71 and 97.25%, respectively, were properly mapped to the reference genome of UCSC hg19. The average sequencing depths were 28.31-, 31.08-, 30.55- and 34.47-fold, and 99.66, 98.96, 99.62, 98.93 of the reference genomes were covered by the clean reads, respectively. Coverage at least 4-fold were 99.32, 98.69, 99.19 and 98.70%, respectively ([Table III](#tIII-mmr-16-06-9464){ref-type="table"}). As shown in [Fig. 1A](#f1-mmr-16-06-9464){ref-type="fig"}, the association between the ratio of bases in each sample and the sequence depth was in accordance with the Poisson distribution. The mean depths and coverage of each chromosome of the reference genome are shown in [Fig. 1B](#f1-mmr-16-06-9464){ref-type="fig"}, showing a mean depth of \~47 and coverage of \~97%, with the exception of sex chromosomes.

### Detection of SNPs and InDels

The detection of SNPs and InDels were performed using SAMtools, and matched to the dbSNP. There were 3,346,792, 3,387,147, 3,334,068 and 3,389,071 SNPs, respectively for YJY, GMY, ZCG and JLY2, and \~6% (191,998, 193,563, 189,761 and 193,356) of these were located in exonic regions. SNPs identified as being locating in coding sequence (CDS) regions constituted \~11, and \~44% were missense mutations (9,519 in 21,419, 9,670 in 21,629, 9,656 in 21,504, and 9,576 in 21,357; [Fig. 2](#f2-mmr-16-06-9464){ref-type="fig"}). Similarly, of the InDels, \~6% were located in exonic regions (24,304 in 443,118, 2,5246 in 461,393, 23,806 in 436,058, 25,672 in 473,617), an average of 647 InDels were located in the CDS, \~12% (75, 73, 78, and 74) were identified as frame shift deletions, and 9% (54, 55, 59, and 55) were frame shift insertions ([Fig. 3](#f3-mmr-16-06-9464){ref-type="fig"}).

### Annotation of SNPs and InDels

The ts/tv ratios of all samples were \~2.2 (YJY, 2.11; GMY, 2.10; ZCG, 2.11; JLY2, 2.10), the numbers of TS and TV types of SNPs were 2,269,999 and 1,076,793, 2,296,037 and 1,091,110, 2,263,437 and 1,070,631, 2,297,128 and 1,091,943 for each sample. Compared with the dbSNP, an average of 98.76% of the SNP sites were matched and an average of 41,563 SNPs were novel in each sequence data (40,762, 41,619, 41,694, 42,176; [Table IV](#tIV-mmr-16-06-9464){ref-type="table"}). For the InDels, there were 443,118, 461,393, 436,058 and 473,617 in YJY, GMY, ZCG and JLY2, respectively, the majority of which were heterozygote and homozygote; \~28.28% (126,222, 130,260, 124,274 and 132,201) were found in the dbSNP, and the remaining were novel ([Table V](#tV-mmr-16-06-9464){ref-type="table"}).

### Analysis of SVs and CNVs

SV identification was performed using Breakdancer 1.4.4 software, the results showed that the largest number of structural variations were deletions with average of 2,422 variations (YJY, 2,193; GMY, 2,390; ZCG, 2,220 and JLY2, 2,886). The majority of the variations were located at intergenic (\~57%) and intron (\~35%) regions. By contrast, the least common structural variation was inversions, with an average of 138 (YJY, 150; GMY, 130; ZCG, 133; JLY2, 138), which were predominantly located in the intergenic, intron and CDS regions ([Table VI](#tVI-mmr-16-06-9464){ref-type="table"}). CNVs were identified using Control-FREEC v6.7 software, which contained deletions and duplications, the majority of which were in intergenic regions (92, 174, 98 and 159) and CDS regions (41, 35, 43 and 42). The frequency of deletion occurrence was higher, compared with that of duplication occurrence in the four samples ([Table VII](#tVII-mmr-16-06-9464){ref-type="table"}).

Discussion
==========

The characteristics of tumor cells include infinite proliferation and growth, evasion of the body\'s immune surveillance, energy metabolism on the basis of glycolysis metabolism, dedifferentiation, and invasion or migration in a clone growth manner. These biological characteristics of tumor cells differ from the basic features and evolution processes of normal cells, and are considered a result of decisive factors and genetics. Therefore, the investigation of cancer from the perspective of molecular genetics has become the mainstream. A study by Boveri ([@b25-mmr-16-06-9464]) suggested that cancer was caused by abnormal genetic material, and that the damage and induced mutation of DNA leading to cancer also indicated the importance of genetic material in cancer. Rather than explaining the role of single genes or single mutations in cancer cells, investigations are now primarily aimed at clarifying the nature of carcinogenesis through identifying whole genome variation. This includes the identification of novel mutation sites and gene mutations associated with tumors, the molecular regulatory network and the cellular signaling pathways, which these mutations are involved in, for determining the cause of cancer from the gene variation profile ([@b26-mmr-16-06-9464]). Several cancer genes and pathways have been identified in cancer genome investigations, including the stromal antigen 2 mutation in transitional cell carcinoma of the bladder ([@b27-mmr-16-06-9464]), FAT atypical cadherin 1, FAT atypical cadherin 2 and zinc finger protein 750 mutations in esophageal squamous cell carcinoma ([@b28-mmr-16-06-9464]) and AT-rich interactive domain-1A, vascular cell adhesion molecule 1 and cyclin-dependent kinase 14 mutations in liver cancer ([@b29-mmr-16-06-9464]).

In the present study, re-sequencing of four tumor genomes was performed from different patients with lung adenocarcinoma, and these sequence data were aligned to reference genome hg19 to obtain information regarding the numbers of SNPs, InDels, SVs and CNVs in each sample, respectively. The alignment results showed that changes of base ratio with sequence depth in each sample were in accordance with the Poisson distribution, and this suggested that the sequencing results were of high quality and coverage.

SNPs can occur anywhere in the genome, including CDS, untranslated region, splicing, non-coding RNA and intergenic regions; they can occur as a synonymous SNP, missense SNP, stopgain and stoploss in the CDS region, which can lead to errors in the amino acid sequence of proteins or in the regulation of translation, thus affecting cell features and function. In the present study, an average of 3,364,269 SNPs was detected in each sample, of which 98.77% were matched to the dbSNP. The ts/tv ratios were all \~2.1, indicating a high level of accuracy of the SNP data (whole genome ratio is \~2.2). InDels of the CDS region and splice site are likely to alter protein translation. Frameshift mutations, in which the base lengths of insertion or deletions are not a multiple of three bases, may lead to changes in the reading frame. The present study also identified numerous InDels in each sample, the majority of which were located in intergenic regions and noncoding regions, and a large proportion of InDels (\~82%) were novel. However, changes in frame coding proteins, including frameshift deletions, frameshift insertions, stopgain and stoploss were present in CDS regions.

SV is widespread in the human genome, and is the source of individual differences and susceptibility to certain diseases. SV also exists in cancer cells, compared with the genome of normal tissue cells and may lead to the occurrence of fusion genes, which may be associated with cancer ([@b30-mmr-16-06-9464]). The results of the present study showed that the most common SV type was deletions, with an average of 2,422 variations. CNV may be an important cause of certain diseases. Deletions and duplications at the chromosome level have become a focus of investigations of several diseases. The results of the present study indicated that deletions and duplications were present in all four samples, predominantly in intergenic regions (92, 174, 98 and 159) and CDS regions (41, 35, 43 and 42).

In conclusion, the present study described the genome re-sequencing results of four patients with lung adenocarcinoma and the alignment results of these sequence data. The SNPs, InDels, SVs and CNVs of each sample were identified, which aligned to the reference genome of hg19, and a simple annotation of SNPs and InDels was performed. Increasing evidence indicates that genetic variation is closely associated with diseases, including cancer. SNPs, InDels, SVs and CNVs may affect gene expression or signaling pathways, which may lead to changes in cell viability and metastasis. The occurrence and progression of lung adenocarcinoma is a complicated process with specific gene expression profile and gene functions, which are the result of genetic variation and/or environmental factors. The results of the present study showed that investigating genome variation in patients with lung adenocarcinoma assists in understanding the mechanism of lung adenocarcinoma oncogenesis. More samples and investigations of specific genetic analysis and functional annotations are required to further examine of the associations between gene variation and lung adenocarcinoma.

The present study was supported by the '12th Five Year' National Science and Technology Supporting Program (grant no. 2011BAI11B16).
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###### 

Patient information.

  Patient   Sex      Age (years)   Cancer                Stage   Tumor sample
  --------- -------- ------------- --------------------- ------- ---------------
  YJY       Female   67            Lung adenocarcinoma   IV      Primary tumor
  GMY       Female   75            Lung adenocarcinoma   IV      Primary tumor
  ZCG       Male     65            Lung adenocarcinoma   IV      Primary tumor
  JLY2      Male     52            Lung adenocarcinoma   IV      Primary tumor

###### 

Quality of sequencing data.

  Sample   Raw reads (n)   Raw data (G)   Clean reads (n)   Effective (%)   Q20 (%)        Q30 (%)        GC (%)
  -------- --------------- -------------- ----------------- --------------- -------------- -------------- --------------
  YJY      621,362,127     93.20          620,492,220       99.86           96.27; 93.27   90.88; 85.32   42.05; 41.99
  GMY      695,467,557     104.32         694,563,450       99.87           96.53; 93.07   91.35; 86.04   40.93; 40.93
  ZCG      680,810,250     102.12         679,993,278       99.88           96.43; 94.08   91.26; 86.94   43.71; 43.66
  JLY2     775,624,875     116.34         774,771,688       99.89           96.55; 93.63   91.38; 86.22   40.95; 40.92

###### 

Summary of sequenced reads aligned to the reference genome of hg19.

  Sample                                                     YJY                    GMY                    ZCG                    JLY2
  ---------------------------------------------------------- ---------------------- ---------------------- ---------------------- ----------------------
  Total                                                      620,492,220 (100%)     694,563,450 (100%)     67,9993,278 (100%)     774771688 (100%)
  Duplicate                                                  62,418,141 (10.10%)    83,850,807 (12.12%)    78,946,241 (11.66%)    98027674 (12.70%)
  Mapped                                                     617,787,854 (99.56%)   691,799,013 (99.60%)   677,069,702 (99.57%)   771,860,901 (99.62%)
  Properly mapped                                            598,003,088 (96.38%)   675,101,840 (97.20%)   664,436,740 (97.71%)   753,442,342 (97.25%)
  PE mapped                                                  615,682036 (99.22%)    689,578,896 (99.28%)   674,885,134 (99.25%)   769,555,296 (99.33%)
  SE mapped                                                  4,211,636 (0.68%)      4,440,234 (0.64%)      4,369,136 (0.64%)      4,611,210 (0.60%)
  With mate mapped to a different chromosome                 3,958,804 (0.64%)      2,711,738 (0.39%)      3,465,530 (0.51%)      2,738,078 (0.35%)
  With mate mapped to a different chromosome \[(mapQ ≥5)\]   2,839,756 (0.46%)      1,788,585 (0.26%)      2,347,772 (0.35%)      1,691,563 (0.22%)
  Average sequencing depth                                   28.31                  31.08                  30.55                  34.47
  Coverage                                                   99.66%                 98.96%                 99.62%                 98.93%
  Coverage at least 4X                                       99.32%                 98.69%                 99.19%                 98.70%
  Coverage at least 10X                                      97.00%                 97.93%                 96.07%                 98.15%
  Coverage at least 20X                                      79.91%                 91.11%                 76.60%                 94.19%

PE, paired-ended reads; SE, single-ended reads; mapQ, map quality which is the effective reading criteria.

###### 

Statistics of single nucleotide polymorphisms for high quality reads from YJY, GMY, ZCG and JLY2 mapped onto the reference genome of hg19.

  Sample             YJY                  GMY                  ZCG                  JLY2
  ------------------ -------------------- -------------------- -------------------- --------------------
  Total              3,346,792            3,387,147            3,334,068            3,389,071
  Heterozygote       1,890,012            1,951,091            1,881,111            1,961,901
  Homozygote         1,456,780            1,436,056            1,452,957            1,427,170
  Transition         2,269,999            2,296,037            2,263,437            2,297,128
  Transversion       1,076,793            1,091,110            1,070,631            1,091,943
  ts/tv              2.11                 2.10                 2.11                 2.10
  dbSNP percentage   3,306,030 (98.78%)   3,345,528 (98.77%)   3,292,374 (98.75%)   3,346,895 (98.76%)
  Novel              40,762               41,619               41,694               42,176
  Novel ts           26,861               27,531               27,471               27,834
  Novel tv           13,901               14,088               14,223               14,342
  Novel ts/tv        1.93                 1.95                 1.93                 1.94

ts, transition; tv, transversion; dbSNP, single nucleotide polymorphism database.

###### 

Statistics of insertions and deletions for high quality reads from YJY, GMY, ZCG and JLY2 mapped onto the reference genome of hg19.

  Sample             YJY                GMY                ZCG                JLY2
  ------------------ ------------------ ------------------ ------------------ ------------------
  Total              443,118            461,393            436,058            473,617
  Heterozygote       191,092            202,768            187,294            207,839
  Homozygote         252,026            258,625            248,764            265,778
  dbSNP percentage   126,222 (28.48%)   130,260 (28.23%)   124,274 (28.50%)   132,201 (27.91%)
  Novel              316,896            331,133            311,784            341,416

dbSNP, single nucleotide polymorphism database.

###### 

Statistics of structural variations for high quality reads from YJY, GMY, ZCG and JLY2 mapped onto the reference genome of hg19.

  Sample   VarType         Total   CDS   Splicing   UTR5   UTR3   Intron   Upstream   Downstream   ncRNA   Intergenic   Unknown
  -------- --------------- ------- ----- ---------- ------ ------ -------- ---------- ------------ ------- ------------ ---------
  YJY      Insertion       295     5     0          1      1      114      2          3            16      153          0
           Inversion       150     33    0          0      0      32       1          0            12      72           0
           Deletion        2,193   49    2          2      5      748      12         20           79      1,276        0
           Translocation   298     3     0          1      4      83       3          0            14      190          0
  GMY      Inversion       130     30    0          0      0      24       1          0            13      62           0
           Deletion        2,390   51    0          2      4      809      14         15           92      1,403        0
           Insertion       176     4     0          0      1      71       3          3            8       86           0
           Translocation   300     1     0          0      10     92       3          0            17      177          0
  ZCG      Deletion        2,220   52    2          3      5      807      24         20           77      1,230        0
           Inversion       133     49    0          0      0      29       1          1            11      42           0
           Insertion       376     7     0          1      0      156      1          4            19      188          0
           Translocation   378     4     0          1      5      110      3          0            19      236          0
  JLY2     Deletion        2,886   57    1          3      8      1,002    13         24           94      1,684        0
           Insertion       631     9     0          1      2      243      6          7            28      335          0
           Inversion       138     29    0          1      0      36       1          0            10      61           0
           Translocation   356     3     0          1      6      101      2          0            18      225          0

VarType, type of variation; CDS, coding sequence; UTR, untranslated region; ncRNA, non-coding RNA.

###### 

Statistics of copy number variations for high quality reads from YJY, GMY, ZCG and JLY2 mapped onto the reference genome of hg19.

  Sample   VarType   Total   CDS   Splicing   UTR5   UTR3   Intron   Upstream   Downstream   ncRNA   Intergenic   Unknown
  -------- --------- ------- ----- ---------- ------ ------ -------- ---------- ------------ ------- ------------ ---------
  YJY      Loss      96      17    0          2      1      16       0          0            4       56           0
           Gain      67      24    0          0      0      2        0          1            4       36           0
  GMY      Gain      82      22    0          0      0      7        3          1            8       41           0
           Loss      195     13    0          1      1      35       2          1            9       133          0
  ZCG      Gain      74      21    0          1      1      4        1          0            9       37           0
           Loss      106     22    0          1      1      13       2          1            5       61           0
  JLY2     Gain      88      22    0          0      0      7        2          1            9       47           0
           Loss      178     20    0          1      1      33       1          3            7       112          0

VarType, type of variation; CDS, coding sequence; UTR, untranslated region; ncRNA, non-coding RNA.
